A Phase I/II, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR610 Given Weekly in Subjects With Solid Tumors

Trial Profile

A Phase I/II, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR610 Given Weekly in Subjects With Solid Tumors

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Tarloxotinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Proacta
  • Most Recent Events

    • 22 Apr 2015 According to a Threshold Pharmaceuticals media release, data from this study were reported at the annual meeting of the American Association for Cancer Research (AACR) 2015.
    • 13 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Mar 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top